{"id":"NCT00069095","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer","officialTitle":"A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) (\"XELOX\") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) (\"FOLFOX-4\") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-07","primaryCompletion":"2006-01","completion":"2009-04","firstPosted":"2003-09-18","resultsPosted":"2016-01-22","lastUpdate":"2016-10-06"},"enrollment":2035,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Colorectal Cancer"],"interventions":[{"type":"DRUG","name":"Oxaliplatin 130 mg/m^2","otherNames":["Eloxatin"]},{"type":"DRUG","name":"Capecitabine 1000 mg/m^2","otherNames":["Xeloda"]},{"type":"DRUG","name":"Bevacizumab 7.5 mg/kg","otherNames":["Avastin"]},{"type":"DRUG","name":"Placebo for bevacizumab 7.5 mg/kg","otherNames":[]},{"type":"DRUG","name":"Oxaliplatin 85 mg/m^2","otherNames":["Eloxatin"]},{"type":"DRUG","name":"Leucovorin 200 mg/m^2","otherNames":[]},{"type":"DRUG","name":"Fluorouracil 400 mg/m^2","otherNames":["Efudex"]},{"type":"DRUG","name":"Bevacizumab 5 mg/kg","otherNames":["Avastin"]},{"type":"DRUG","name":"Placebo for bevacizumab 5 mg/kg","otherNames":[]}],"arms":[{"label":"XELOX (oxaliplatin+capecitabine)","type":"EXPERIMENTAL"},{"label":"XELOX (oxaliplatin+capecitabine) + bevacizumab","type":"EXPERIMENTAL"},{"label":"FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil)","type":"ACTIVE_COMPARATOR"},{"label":"FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil) + bevacizumab","type":"ACTIVE_COMPARATOR"}],"summary":"This 4 arm study assessed the efficacy and safety of oral capecitabine (Xeloda) or intravenous (iv) fluorouracil/leucovorin, in combination with iv oxaliplatin (Eloxatin) with or without iv bevacizumab (Avastin), as a first-line treatment in patients with metastatic colorectal cancer. Patients were randomized to receive 1) XELOX (Xeloda 1000 mg/m\\^2 orally \\[po\\] twice a day \\[bid\\] on Days 1-15 + oxaliplatin in 3 week cycles), 2) FOLFOX-4 (oxaliplatin + leucovorin + fluorouracil \\[5-FU\\] in 2 week cycles), 3) XELOX + bevacizumab (7.5 mg iv on Day 1 in 3 week cycles), or 4) FOLFOX-4 + bevacizumab (5 mg iv on Day 1 in 2 week cycles).","primaryOutcome":{"measure":"Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4","timeFrame":"Baseline until disease progression or death, approximately 2 years 6 months","effectByArm":[{"arm":"FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV","deltaMin":259,"sd":null},{"arm":"XELOX/XELOX+P/XELOX+BV","deltaMin":241,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":236,"countries":["United States","Australia","Austria","Brazil","Canada","China","Czechia","Denmark","Finland","France","Germany","Guatemala","Hong Kong","Hungary","Ireland","Israel","Italy","Mexico","New Zealand","Norway","Panama","Portugal","Puerto Rico","Russia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":117,"n":316},"commonTop":["Nausea","Diarrhoea","Fatigue","Vomiting","Neutropenia"]}}